Human Immunodeficiency Virus-Associated Nephropathy: A Primary Care Perspective

Archives of Internal Medicine

Volumn 164, Issue 3, 2004, Pages 333-336

  Olatinwo, Toyin ^a,b   Hewitt, Ross G ^a,b   Venuto, Rocco C ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b ERIE COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CAPTOPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; GLUCOCORTICOID; PREDNISONE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICAN AMERICAN; CLINICAL FEATURE; CREATININE CLEARANCE; DRUG MEGADOSE; FAMILY HISTORY; FOCAL GLOMERULOSCLEROSIS; HEMODIALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED NEPHROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; KIDNEY FAILURE; LYMPHOCYTE COUNT; MONOTHERAPY; PATHOGENESIS; PATHOLOGY; PRIMARY HEALTH CARE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK FACTOR; TREATMENT PLANNING; UNITED STATES;

AIDS-ASSOCIATED NEPHROPATHY; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY FAILURE; PRIMARY HEALTH CARE; RISK FACTORS; UNITED STATES;

EID: 0842327164     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.3.333     Document Type: Review

References (39)

1. Rao TKS, Filippone EJ, Nicastri AD, et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med. 1984;310:669-673.
2. D'Agati V, Suh JI, Carbone L, Cheng JT, Appel G. Pathology of HIV-associated nephropathy: a detailed morphologic and comparative study. Kidney Int. 1989;35:1358-1370.
3. Cohen AH, Nast CC. HIV-associated nephropathy: a unique combined glomerular, tubular, and interstitial lesion. Mod Pathol 1988;1:87-97.
4. Szczech LA, Gange SJ, van der Horst C, et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int. 2002;61:195-202.
5. Gardner L, Holmberg S, Williamson J, et al. Kidney dysfunction and mortality in HIV-infected women. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-19, 2000; Toronto, Ontario. Washington, DC: American Society for Microbiology; 2000. Abstract 2061.
6. Ross MJ, Klotman PE, Winston JA. HIV-associated nephropathy: case study and review of the literature. AIDS Patient Care STDs. 2000;14:637-645.
7. Shahinian V, Rajaraman S, Borucki M, Grady J, Hollander WM, Ahuja TS. Prevalence of HIV-associated nephropathy in autopsies of HIV infected patients. Am J Kidney Dis. 2000;35:884-888.
8. Ahuja TS, Borucki M, Funtanilla M, Shahinian V, Hollander M, Rajaraman S. Is the prevalence of HIV-associated nephropathy decreasing? Am J Nephrol. 1999;19:655-659.
9. Centers for Disease Control and Prevention. The global HIV and AIDS epidemic, 2001. MMWR Morb Mortal Wkly Rep. 2001;50:434-439.
10. Szczech LA. Recent developments and current issues in HIV-related renal disease. MedGenMed [serial online]. 2001;3. Available at http://www .medscape.com/viewarticle/408276. Accessed October 16, 2003.
11. Rao TK. Human immunodeficiency virus infection and renal failure. Infect Dis Clin North Am. 2001;15:833-850.
12. Carbone L, D'Agati V, Cheng J, Appel GB. Course and prognosis of human immunodeficiency virus-associated nephropathy. Am J Med. 1989;87:389-395.
13. Levin ML, Palella F, Shah S, et al. HIV-associated nephropathy occurring before HIV antibody seroconversion. Am J Kidney Dis. 2001;37:E39.
14. Szabo S, James C, Telford G. Unusual presentations of primary human immunodeficiency virus infection. AIDS Patient Care STDs. 2002;16:251-254.
15. Laradi A, Mallet A, Beaufils H, et al, for the Groupe D'Etudes Néphrologiques d'Ile de France. HIV-associated nephropathy: outcome and prognosis factors. J Am Soc Nephrol. 1998;9:2327-2335.
16. Burns GC, Paul SK, Toth IR, Sivak SL. Effects of angiotensin-converting enzyme inhibition in HIV-associated nphropathy. J Am Soc Nephrol. 1997;8:1140-1146.
17. Kimmel PL, Ferreira-Centeno A, Farkas-Szallasi T, Abraham AA, Garrett CT. Viral DNA in microdissected renal biopsy tissue from HIV infected patients with nephrotic syndrome. Kidney Int. 1993;43:1347-1352
18. Bruggeman LA, Ross MD, Tangi N, et al. Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol. 2000;11:2079-2087.
19. Winston JA, Bruggeman LA, Ross MD, et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med. 2001;344:1979-1984.
20. Freedman BI, Soucie JM, Stone SM, Pegram S. Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am J Kidney Dis. 1999;34:254-258.
21. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
22. De Jong PE, Heeg JE, Apperloo AJ, de Zeeuw D. Angiotensin-1 converting enzyme inhibition: clinical effects in chronic renal disease. Am J Kidney Dis. 1991;17:85-88.
23. Kimmel PL, Mishkin GJ, Umana WO. Captopril and renal survival in patients with human immunodeficiency virus nephropathy. Am J Kidney Dis. 1996;28:202-208.
24. Eustace JA, Nuermberger E, Choi M, et al. Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int. 2000;58:1253-1260.
25. Smith MC, Pawar R, Carey JT, et al. Effect of corticosteroid therapy on human immunodeficiency virus-associated nephropathy. Am J Med. 1994;97:145-151.
26. Ifudu O, Rao TK, Tan CC, et al. Zidovudine is beneficial in human immunodeficiency virus associated nephropathy. Am J Nephrol. 1995;15:217-221.
27. Michel C, Dosquet P, Ronco P, et al. Nephropathy associated with infection by human immunodeficiency virus: a report on 11 cases including 6 treated with zidovudine. Nephron. 1992;62:434-440.
28. Babut-Gay ML, Echard M, Kleinknecht D, Meyrier A. Zidovudine and nephropathy with human immunodeficiency virus (HIV) infection. Ann Intern Med. 1989;111:856-857.
29. Szczech LA, Edwards LJ, van der Horst C, Bartlett JA, Heald EA, Svetkey LP. Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. Clin Nephrol. 2002;57:336-341.
30. Cosgrove CJ, Abu-Alfa AK, Perazella MA. Observations on HIV-associated renal disease in the era of highly active antiretroviral therapy. Am J Med Sci. 2002;323:102-106.
31. Chemlal K, Nochy D, Kenouch S, et al. Dramatic improvement of renal dysfunction in a human immunodeficiency virus-infected woman treated with highly active antiretroviral therapy. Clin Infect Dis. 2000;31:805-806.
32. Beties MG, Weening J, Krediet RT. Diagnosis and treatment of HIV-associated nephropathy. Neth J Med. 2001;59:111-117.
33. Wali RK, Drachenberg CI, Papadimitriou JC, Keay S, Ramos E. HIV-1-associated nephropathy and response to highly active antiretroviral therapy. Lancet. 1998;352:783-784.
34. Ahuja TS, Borucki M, Grady J. Highly active antiretroviral therapy improves survival of HIV-infected hemodialysis patients. Am J Kidney Dis. 2000;36:574-580.
35. Abbott KC, Hypolite I, Welch PG, Agodoa LY. Human immunodeficiency virus/acquired immunodeficiency syndrome-associated nephropathy at endstage renal disease in the United States: patient characteristics in the pre highly active antiretroviral therapy era. J Nephrol. 2001;14:377-383.
36. Panel on clinical practices for treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at: http://www.aidsinfo.nih.gov /guidelines. Accessed October 16, 2003.
37. Dybui M, Fauci A, Bartlett JG, Kaplan, JE, Pau AK, for the Panel on Clinical Practices for HIV. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med. 2002;137:381-433.
38. National Kidney Foundation. The National Kidney Foundation Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Part 5, Guideline 5. Available at www.kidney.org/professionals/doqi/kdoki/p5_lab_g5.htm.
39. Winston JA. The increasing problem of HIV-associated nephropathy [editorial comment]. AIDS Read. 2002;12:110-111.